VINC logo

Vincerx Pharma Stock Price

Symbol: OTCPK:VINCMarket Cap: US$189.0kCategory: Pharmaceuticals & Biotech

VINC Share Price Performance

US$0.036
-11.90 (-99.70%)
US$0.036
-11.90 (-99.70%)
Price US$0.036

VINC Community Narratives

There are no narratives available yet.

VINC Community Fair Values

    Recent VINC News & Updates

    No updates

    Vincerx Pharma, Inc. Key Details

    US$0

    Revenue

    US$0

    Cost of Revenue

    US$0

    Gross Profit

    US$22.6m

    Other Expenses

    -US$22.6m

    Earnings

    Last Reported Earnings
    Mar 31, 2025
    Next Reporting Earnings
    n/a
    Earnings per share (EPS)
    -4.33
    Gross Margin
    0%
    Net Profit Margin
    0%
    Debt/Equity Ratio
    0%

    Vincerx Pharma, Inc. Competitors

     
     
     
     
     
     
     
     
     
     
     
     

    About VINC

    Founded
    2019
    Employees
    13
    CEO
    Raquel Izumi
    WebsiteView website
    vincerx.com

    Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory acute myeloid leukemia, higher-risk MDS, and B-cell acute lymphoblastic leukemia; VIP236, an SMDC, which is in Phase 1 dose-escalation study for the treatment of patients with advanced or metastatic solid tumors; and VIP924, an anti-CXCR5 ADC that leverages the same effector chemistry in preclinical studies for b-cell malignancies. It has a collaboration with the National Institutes of Health for the Phase 1 dose-escalation of enitociclib, a highly selective cyclin-dependent kinase 9 inhibitor. The company was formerly known as Vincera Pharma, Inc. and changed its name to Vincerx Pharma, Inc. in January 2021. Vincerx Pharma, Inc. was founded in 2019 and is headquartered in San Mateo, California.

    U.S. Market Performance

    • 7 Days: -2.7%
    • 3 Months: 11.4%
    • 1 Year: 20.5%
    • Year to Date: 5.9%
    In the last week, the market has fallen 2.7%, dragged down most by the Financials. In the last year, the market is actually up 18%. Earnings are forecast to grow by 15% annually. Market details ›
    This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
    Continue reading